Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients

Currently, amrubicin is permitted for relapsed small-cell lung carcinoma (SCLC) only in Japan. The efficacy and adverse effects of amrubicin as reported by previous studies varied greatly. The inclusion criterion was a prospective study that was able to provide data for efficacy and safety by the AM...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Horita, Nobuyuki, Yamamoto, Masaki, Sato, Takashi, Tsukahara, Toshinori, Nagakura, Hideyuki, Tashiro, Ken, Shibata, Yuji, Watanabe, Hiroki, Nagai, Kenjiro, Nakashima, Kentaro, Ushio, Ryota, Ikeda, Misako, Kobayashi, Nobuaki, Shinkai, Masaharu, Kudo, Makoto, Kaneko, Takeshi
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4707435/
https://ncbi.nlm.nih.gov/pubmed/26750506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep18999
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky